Global Neuroblastoma Chemotherapy Drugs Supply, Demand and Key Producers, 2023-2029

Description

The global Neuroblastoma Chemotherapy Drugs market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.

This report studies the global Neuroblastoma Chemotherapy Drugs production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Neuroblastoma Chemotherapy Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Neuroblastoma Chemotherapy Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Neuroblastoma Chemotherapy Drugs total production and demand, 2018-2029, (K Units)
Global Neuroblastoma Chemotherapy Drugs total production value, 2018-2029, (USD Million)
Global Neuroblastoma Chemotherapy Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Neuroblastoma Chemotherapy Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Neuroblastoma Chemotherapy Drugs domestic production, consumption, key domestic manufacturers and share
Global Neuroblastoma Chemotherapy Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Neuroblastoma Chemotherapy Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Neuroblastoma Chemotherapy Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Neuroblastoma Chemotherapy Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Neuroblastoma Chemotherapy Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Neuroblastoma Chemotherapy Drugs Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Neuroblastoma Chemotherapy Drugs Market, Segmentation by Type
    Cyclophosphamide
    Cisplatin or Carboplatin
    Vincristine
    Doxorubicin (Adriamycin)
    Etoposide
    Other

Global Neuroblastoma Chemotherapy Drugs Market, Segmentation by Application
    Hospital
    Clinic
    Other

Companies Profiled:
    Baxter Healthcare
    Ingenus Pharmaceuticals
    ANI Pharmaceuticals
    Teva Pharmaceuticals
    Qilu Pharmaceutical
    Pfizer
    Hikma Pharmaceuticals
    Fresenius Kabi
    Accord Healthcare
    Viatris

Key Questions Answered
1. How big is the global Neuroblastoma Chemotherapy Drugs market?
2. What is the demand of the global Neuroblastoma Chemotherapy Drugs market?
3. What is the year over year growth of the global Neuroblastoma Chemotherapy Drugs market?
4. What is the production and production value of the global Neuroblastoma Chemotherapy Drugs market?
5. Who are the key producers in the global Neuroblastoma Chemotherapy Drugs market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Neuroblastoma Chemotherapy Drugs Introduction
    1.2 World Neuroblastoma Chemotherapy Drugs Supply & Forecast
        1.2.1 World Neuroblastoma Chemotherapy Drugs Production Value (2018 & 2022 & 2029)
        1.2.2 World Neuroblastoma Chemotherapy Drugs Production (2018-2029)
        1.2.3 World Neuroblastoma Chemotherapy Drugs Pricing Trends (2018-2029)
    1.3 World Neuroblastoma Chemotherapy Drugs Production by Region (Based on Production Site)
        1.3.1 World Neuroblastoma Chemotherapy Drugs Production Value by Region (2018-2029)
        1.3.2 World Neuroblastoma Chemotherapy Drugs Production by Region (2018-2029)
        1.3.3 World Neuroblastoma Chemotherapy Drugs Average Price by Region (2018-2029)
        1.3.4 North America Neuroblastoma Chemotherapy Drugs Production (2018-2029)
        1.3.5 Europe Neuroblastoma Chemotherapy Drugs Production (2018-2029)
        1.3.6 China Neuroblastoma Chemotherapy Drugs Production (2018-2029)
        1.3.7 Japan Neuroblastoma Chemotherapy Drugs Production (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Neuroblastoma Chemotherapy Drugs Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Neuroblastoma Chemotherapy Drugs Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Neuroblastoma Chemotherapy Drugs Demand (2018-2029)
    2.2 World Neuroblastoma Chemotherapy Drugs Consumption by Region
        2.2.1 World Neuroblastoma Chemotherapy Drugs Consumption by Region (2018-2023)
        2.2.2 World Neuroblastoma Chemotherapy Drugs Consumption Forecast by Region (2024-2029)
    2.3 United States Neuroblastoma Chemotherapy Drugs Consumption (2018-2029)
    2.4 China Neuroblastoma Chemotherapy Drugs Consumption (2018-2029)
    2.5 Europe Neuroblastoma Chemotherapy Drugs Consumption (2018-2029)
    2.6 Japan Neuroblastoma Chemotherapy Drugs Consumption (2018-2029)
    2.7 South Korea Neuroblastoma Chemotherapy Drugs Consumption (2018-2029)
    2.8 ASEAN Neuroblastoma Chemotherapy Drugs Consumption (2018-2029)
    2.9 India Neuroblastoma Chemotherapy Drugs Consumption (2018-2029)

3 World Neuroblastoma Chemotherapy Drugs Manufacturers Competitive Analysis
    3.1 World Neuroblastoma Chemotherapy Drugs Production Value by Manufacturer (2018-2023)
    3.2 World Neuroblastoma Chemotherapy Drugs Production by Manufacturer (2018-2023)
    3.3 World Neuroblastoma Chemotherapy Drugs Average Price by Manufacturer (2018-2023)
    3.4 Neuroblastoma Chemotherapy Drugs Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Neuroblastoma Chemotherapy Drugs Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Neuroblastoma Chemotherapy Drugs in 2022
        3.5.3 Global Concentration Ratios (CR8) for Neuroblastoma Chemotherapy Drugs in 2022
    3.6 Neuroblastoma Chemotherapy Drugs Market: Overall Company Footprint Analysis
        3.6.1 Neuroblastoma Chemotherapy Drugs Market: Region Footprint
        3.6.2 Neuroblastoma Chemotherapy Drugs Market: Company Product Type Footprint
        3.6.3 Neuroblastoma Chemotherapy Drugs Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Neuroblastoma Chemotherapy Drugs Production Value Comparison
        4.1.1 United States VS China: Neuroblastoma Chemotherapy Drugs Production Value Comparison (2018 & 2022 & 2029)
        4.1.2 United States VS China: Neuroblastoma Chemotherapy Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States VS China: Neuroblastoma Chemotherapy Drugs Production Comparison
        4.2.1 United States VS China: Neuroblastoma Chemotherapy Drugs Production Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Neuroblastoma Chemotherapy Drugs Production Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States VS China: Neuroblastoma Chemotherapy Drugs Consumption Comparison
        4.3.1 United States VS China: Neuroblastoma Chemotherapy Drugs Consumption Comparison (2018 & 2022 & 2029)
        4.3.2 United States VS China: Neuroblastoma Chemotherapy Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
    4.4 United States Based Neuroblastoma Chemotherapy Drugs Manufacturers and Market Share, 2018-2023
        4.4.1 United States Based Neuroblastoma Chemotherapy Drugs Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Value (2018-2023)
        4.4.3 United States Based Manufacturers Neuroblastoma Chemotherapy Drugs Production (2018-2023)
    4.5 China Based Neuroblastoma Chemotherapy Drugs Manufacturers and Market Share
        4.5.1 China Based Neuroblastoma Chemotherapy Drugs Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Value (2018-2023)
        4.5.3 China Based Manufacturers Neuroblastoma Chemotherapy Drugs Production (2018-2023)
    4.6 Rest of World Based Neuroblastoma Chemotherapy Drugs Manufacturers and Market Share, 2018-2023
        4.6.1 Rest of World Based Neuroblastoma Chemotherapy Drugs Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Value (2018-2023)
        4.6.3 Rest of World Based Manufacturers Neuroblastoma Chemotherapy Drugs Production (2018-2023)

5 Market Analysis by Type
    5.1 World Neuroblastoma Chemotherapy Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Cyclophosphamide
        5.2.2 Cisplatin or Carboplatin
        5.2.3 Vincristine
        5.2.4 Doxorubicin (Adriamycin)
        5.2.5 Etoposide
        5.2.6 Other
    5.3 Market Segment by Type
        5.3.1 World Neuroblastoma Chemotherapy Drugs Production by Type (2018-2029)
        5.3.2 World Neuroblastoma Chemotherapy Drugs Production Value by Type (2018-2029)
        5.3.3 World Neuroblastoma Chemotherapy Drugs Average Price by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Neuroblastoma Chemotherapy Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hospital
        6.2.2 Clinic
        6.2.3 Other
    6.3 Market Segment by Application
        6.3.1 World Neuroblastoma Chemotherapy Drugs Production by Application (2018-2029)
        6.3.2 World Neuroblastoma Chemotherapy Drugs Production Value by Application (2018-2029)
        6.3.3 World Neuroblastoma Chemotherapy Drugs Average Price by Application (2018-2029)

7 Company Profiles
    7.1 Baxter Healthcare
        7.1.1 Baxter Healthcare Details
        7.1.2 Baxter Healthcare Major Business
        7.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
        7.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.1.5 Baxter Healthcare Recent Developments/Updates
        7.1.6 Baxter Healthcare Competitive Strengths & Weaknesses
    7.2 Ingenus Pharmaceuticals
        7.2.1 Ingenus Pharmaceuticals Details
        7.2.2 Ingenus Pharmaceuticals Major Business
        7.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
        7.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
        7.2.6 Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
    7.3 ANI Pharmaceuticals
        7.3.1 ANI Pharmaceuticals Details
        7.3.2 ANI Pharmaceuticals Major Business
        7.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
        7.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.3.5 ANI Pharmaceuticals Recent Developments/Updates
        7.3.6 ANI Pharmaceuticals Competitive Strengths & Weaknesses
    7.4 Teva Pharmaceuticals
        7.4.1 Teva Pharmaceuticals Details
        7.4.2 Teva Pharmaceuticals Major Business
        7.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
        7.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.4.5 Teva Pharmaceuticals Recent Developments/Updates
        7.4.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
    7.5 Qilu Pharmaceutical
        7.5.1 Qilu Pharmaceutical Details
        7.5.2 Qilu Pharmaceutical Major Business
        7.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
        7.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.5.5 Qilu Pharmaceutical Recent Developments/Updates
        7.5.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
    7.6 Pfizer
        7.6.1 Pfizer Details
        7.6.2 Pfizer Major Business
        7.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
        7.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.6.5 Pfizer Recent Developments/Updates
        7.6.6 Pfizer Competitive Strengths & Weaknesses
    7.7 Hikma Pharmaceuticals
        7.7.1 Hikma Pharmaceuticals Details
        7.7.2 Hikma Pharmaceuticals Major Business
        7.7.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
        7.7.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.7.5 Hikma Pharmaceuticals Recent Developments/Updates
        7.7.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
    7.8 Fresenius Kabi
        7.8.1 Fresenius Kabi Details
        7.8.2 Fresenius Kabi Major Business
        7.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
        7.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.8.5 Fresenius Kabi Recent Developments/Updates
        7.8.6 Fresenius Kabi Competitive Strengths & Weaknesses
    7.9 Accord Healthcare
        7.9.1 Accord Healthcare Details
        7.9.2 Accord Healthcare Major Business
        7.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
        7.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.9.5 Accord Healthcare Recent Developments/Updates
        7.9.6 Accord Healthcare Competitive Strengths & Weaknesses
    7.10 Viatris
        7.10.1 Viatris Details
        7.10.2 Viatris Major Business
        7.10.3 Viatris Neuroblastoma Chemotherapy Drugs Product and Services
        7.10.4 Viatris Neuroblastoma Chemotherapy Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.10.5 Viatris Recent Developments/Updates
        7.10.6 Viatris Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Neuroblastoma Chemotherapy Drugs Industry Chain
    8.2 Neuroblastoma Chemotherapy Drugs Upstream Analysis
        8.2.1 Neuroblastoma Chemotherapy Drugs Core Raw Materials
        8.2.2 Main Manufacturers of Neuroblastoma Chemotherapy Drugs Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Neuroblastoma Chemotherapy Drugs Production Mode
    8.6 Neuroblastoma Chemotherapy Drugs Procurement Model
    8.7 Neuroblastoma Chemotherapy Drugs Industry Sales Model and Sales Channels
        8.7.1 Neuroblastoma Chemotherapy Drugs Sales Model
        8.7.2 Neuroblastoma Chemotherapy Drugs Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Neuroblastoma Chemotherapy Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)
    Table 2. World Neuroblastoma Chemotherapy Drugs Production Value by Region (2018-2023) & (USD Million)
    Table 3. World Neuroblastoma Chemotherapy Drugs Production Value by Region (2024-2029) & (USD Million)
    Table 4. World Neuroblastoma Chemotherapy Drugs Production Value Market Share by Region (2018-2023)
    Table 5. World Neuroblastoma Chemotherapy Drugs Production Value Market Share by Region (2024-2029)
    Table 6. World Neuroblastoma Chemotherapy Drugs Production by Region (2018-2023) & (K Units)
    Table 7. World Neuroblastoma Chemotherapy Drugs Production by Region (2024-2029) & (K Units)
    Table 8. World Neuroblastoma Chemotherapy Drugs Production Market Share by Region (2018-2023)
    Table 9. World Neuroblastoma Chemotherapy Drugs Production Market Share by Region (2024-2029)
    Table 10. World Neuroblastoma Chemotherapy Drugs Average Price by Region (2018-2023) & (US$/Unit)
    Table 11. World Neuroblastoma Chemotherapy Drugs Average Price by Region (2024-2029) & (US$/Unit)
    Table 12. Neuroblastoma Chemotherapy Drugs Major Market Trends
    Table 13. World Neuroblastoma Chemotherapy Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
    Table 14. World Neuroblastoma Chemotherapy Drugs Consumption by Region (2018-2023) & (K Units)
    Table 15. World Neuroblastoma Chemotherapy Drugs Consumption Forecast by Region (2024-2029) & (K Units)
    Table 16. World Neuroblastoma Chemotherapy Drugs Production Value by Manufacturer (2018-2023) & (USD Million)
    Table 17. Production Value Market Share of Key Neuroblastoma Chemotherapy Drugs Producers in 2022
    Table 18. World Neuroblastoma Chemotherapy Drugs Production by Manufacturer (2018-2023) & (K Units)
    Table 19. Production Market Share of Key Neuroblastoma Chemotherapy Drugs Producers in 2022
    Table 20. World Neuroblastoma Chemotherapy Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 21. Global Neuroblastoma Chemotherapy Drugs Company Evaluation Quadrant
    Table 22. World Neuroblastoma Chemotherapy Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022
    Table 23. Head Office and Neuroblastoma Chemotherapy Drugs Production Site of Key Manufacturer
    Table 24. Neuroblastoma Chemotherapy Drugs Market: Company Product Type Footprint
    Table 25. Neuroblastoma Chemotherapy Drugs Market: Company Product Application Footprint
    Table 26. Neuroblastoma Chemotherapy Drugs Competitive Factors
    Table 27. Neuroblastoma Chemotherapy Drugs New Entrant and Capacity Expansion Plans
    Table 28. Neuroblastoma Chemotherapy Drugs Mergers & Acquisitions Activity
    Table 29. United States VS China Neuroblastoma Chemotherapy Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 30. United States VS China Neuroblastoma Chemotherapy Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 31. United States VS China Neuroblastoma Chemotherapy Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 32. United States Based Neuroblastoma Chemotherapy Drugs Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Value, (2018-2023) & (USD Million)
    Table 34. United States Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Value Market Share (2018-2023)
    Table 35. United States Based Manufacturers Neuroblastoma Chemotherapy Drugs Production (2018-2023) & (K Units)
    Table 36. United States Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Market Share (2018-2023)
    Table 37. China Based Neuroblastoma Chemotherapy Drugs Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Value, (2018-2023) & (USD Million)
    Table 39. China Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Value Market Share (2018-2023)
    Table 40. China Based Manufacturers Neuroblastoma Chemotherapy Drugs Production (2018-2023) & (K Units)
    Table 41. China Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Market Share (2018-2023)
    Table 42. Rest of World Based Neuroblastoma Chemotherapy Drugs Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Value, (2018-2023) & (USD Million)
    Table 44. Rest of World Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Value Market Share (2018-2023)
    Table 45. Rest of World Based Manufacturers Neuroblastoma Chemotherapy Drugs Production (2018-2023) & (K Units)
    Table 46. Rest of World Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Market Share (2018-2023)
    Table 47. World Neuroblastoma Chemotherapy Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 48. World Neuroblastoma Chemotherapy Drugs Production by Type (2018-2023) & (K Units)
    Table 49. World Neuroblastoma Chemotherapy Drugs Production by Type (2024-2029) & (K Units)
    Table 50. World Neuroblastoma Chemotherapy Drugs Production Value by Type (2018-2023) & (USD Million)
    Table 51. World Neuroblastoma Chemotherapy Drugs Production Value by Type (2024-2029) & (USD Million)
    Table 52. World Neuroblastoma Chemotherapy Drugs Average Price by Type (2018-2023) & (US$/Unit)
    Table 53. World Neuroblastoma Chemotherapy Drugs Average Price by Type (2024-2029) & (US$/Unit)
    Table 54. World Neuroblastoma Chemotherapy Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 55. World Neuroblastoma Chemotherapy Drugs Production by Application (2018-2023) & (K Units)
    Table 56. World Neuroblastoma Chemotherapy Drugs Production by Application (2024-2029) & (K Units)
    Table 57. World Neuroblastoma Chemotherapy Drugs Production Value by Application (2018-2023) & (USD Million)
    Table 58. World Neuroblastoma Chemotherapy Drugs Production Value by Application (2024-2029) & (USD Million)
    Table 59. World Neuroblastoma Chemotherapy Drugs Average Price by Application (2018-2023) & (US$/Unit)
    Table 60. World Neuroblastoma Chemotherapy Drugs Average Price by Application (2024-2029) & (US$/Unit)
    Table 61. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
    Table 62. Baxter Healthcare Major Business
    Table 63. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
    Table 64. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 65. Baxter Healthcare Recent Developments/Updates
    Table 66. Baxter Healthcare Competitive Strengths & Weaknesses
    Table 67. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 68. Ingenus Pharmaceuticals Major Business
    Table 69. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    Table 70. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 71. Ingenus Pharmaceuticals Recent Developments/Updates
    Table 72. Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
    Table 73. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 74. ANI Pharmaceuticals Major Business
    Table 75. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    Table 76. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. ANI Pharmaceuticals Recent Developments/Updates
    Table 78. ANI Pharmaceuticals Competitive Strengths & Weaknesses
    Table 79. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 80. Teva Pharmaceuticals Major Business
    Table 81. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    Table 82. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 83. Teva Pharmaceuticals Recent Developments/Updates
    Table 84. Teva Pharmaceuticals Competitive Strengths & Weaknesses
    Table 85. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
    Table 86. Qilu Pharmaceutical Major Business
    Table 87. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
    Table 88. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. Qilu Pharmaceutical Recent Developments/Updates
    Table 90. Qilu Pharmaceutical Competitive Strengths & Weaknesses
    Table 91. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 92. Pfizer Major Business
    Table 93. Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
    Table 94. Pfizer Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 95. Pfizer Recent Developments/Updates
    Table 96. Pfizer Competitive Strengths & Weaknesses
    Table 97. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 98. Hikma Pharmaceuticals Major Business
    Table 99. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    Table 100. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 101. Hikma Pharmaceuticals Recent Developments/Updates
    Table 102. Hikma Pharmaceuticals Competitive Strengths & Weaknesses
    Table 103. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
    Table 104. Fresenius Kabi Major Business
    Table 105. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
    Table 106. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 107. Fresenius Kabi Recent Developments/Updates
    Table 108. Fresenius Kabi Competitive Strengths & Weaknesses
    Table 109. Accord Healthcare Basic Information, Manufacturing Base and Competitors
    Table 110. Accord Healthcare Major Business
    Table 111. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
    Table 112. Accord Healthcare Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 113. Accord Healthcare Recent Developments/Updates
    Table 114. Viatris Basic Information, Manufacturing Base and Competitors
    Table 115. Viatris Major Business
    Table 116. Viatris Neuroblastoma Chemotherapy Drugs Product and Services
    Table 117. Viatris Neuroblastoma Chemotherapy Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 118. Global Key Players of Neuroblastoma Chemotherapy Drugs Upstream (Raw Materials)
    Table 119. Neuroblastoma Chemotherapy Drugs Typical Customers
    Table 120. Neuroblastoma Chemotherapy Drugs Typical Distributors
List of Figure
    Figure 1. Neuroblastoma Chemotherapy Drugs Picture
    Figure 2. World Neuroblastoma Chemotherapy Drugs Production Value: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Neuroblastoma Chemotherapy Drugs Production Value and Forecast (2018-2029) & (USD Million)
    Figure 4. World Neuroblastoma Chemotherapy Drugs Production (2018-2029) & (K Units)
    Figure 5. World Neuroblastoma Chemotherapy Drugs Average Price (2018-2029) & (US$/Unit)
    Figure 6. World Neuroblastoma Chemotherapy Drugs Production Value Market Share by Region (2018-2029)
    Figure 7. World Neuroblastoma Chemotherapy Drugs Production Market Share by Region (2018-2029)
    Figure 8. North America Neuroblastoma Chemotherapy Drugs Production (2018-2029) & (K Units)
    Figure 9. Europe Neuroblastoma Chemotherapy Drugs Production (2018-2029) & (K Units)
    Figure 10. China Neuroblastoma Chemotherapy Drugs Production (2018-2029) & (K Units)
    Figure 11. Japan Neuroblastoma Chemotherapy Drugs Production (2018-2029) & (K Units)
    Figure 12. Neuroblastoma Chemotherapy Drugs Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Neuroblastoma Chemotherapy Drugs Consumption (2018-2029) & (K Units)
    Figure 15. World Neuroblastoma Chemotherapy Drugs Consumption Market Share by Region (2018-2029)
    Figure 16. United States Neuroblastoma Chemotherapy Drugs Consumption (2018-2029) & (K Units)
    Figure 17. China Neuroblastoma Chemotherapy Drugs Consumption (2018-2029) & (K Units)
    Figure 18. Europe Neuroblastoma Chemotherapy Drugs Consumption (2018-2029) & (K Units)
    Figure 19. Japan Neuroblastoma Chemotherapy Drugs Consumption (2018-2029) & (K Units)
    Figure 20. South Korea Neuroblastoma Chemotherapy Drugs Consumption (2018-2029) & (K Units)
    Figure 21. ASEAN Neuroblastoma Chemotherapy Drugs Consumption (2018-2029) & (K Units)
    Figure 22. India Neuroblastoma Chemotherapy Drugs Consumption (2018-2029) & (K Units)
    Figure 23. Producer Shipments of Neuroblastoma Chemotherapy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Neuroblastoma Chemotherapy Drugs Markets in 2022
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Neuroblastoma Chemotherapy Drugs Markets in 2022
    Figure 26. United States VS China: Neuroblastoma Chemotherapy Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 27. United States VS China: Neuroblastoma Chemotherapy Drugs Production Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Neuroblastoma Chemotherapy Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. United States Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Market Share 2022
    Figure 30. China Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Market Share 2022
    Figure 31. Rest of World Based Manufacturers Neuroblastoma Chemotherapy Drugs Production Market Share 2022
    Figure 32. World Neuroblastoma Chemotherapy Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 33. World Neuroblastoma Chemotherapy Drugs Production Value Market Share by Type in 2022
    Figure 34. Cyclophosphamide
    Figure 35. Cisplatin or Carboplatin
    Figure 36. Vincristine
    Figure 37. Doxorubicin (Adriamycin)
    Figure 38. Etoposide
    Figure 39. Other
    Figure 40. World Neuroblastoma Chemotherapy Drugs Production Market Share by Type (2018-2029)
    Figure 41. World Neuroblastoma Chemotherapy Drugs Production Value Market Share by Type (2018-2029)
    Figure 42. World Neuroblastoma Chemotherapy Drugs Average Price by Type (2018-2029) & (US$/Unit)
    Figure 43. World Neuroblastoma Chemotherapy Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 44. World Neuroblastoma Chemotherapy Drugs Production Value Market Share by Application in 2022
    Figure 45. Hospital
    Figure 46. Clinic
    Figure 47. Other
    Figure 48. World Neuroblastoma Chemotherapy Drugs Production Market Share by Application (2018-2029)
    Figure 49. World Neuroblastoma Chemotherapy Drugs Production Value Market Share by Application (2018-2029)
    Figure 50. World Neuroblastoma Chemotherapy Drugs Average Price by Application (2018-2029) & (US$/Unit)
    Figure 51. Neuroblastoma Chemotherapy Drugs Industry Chain
    Figure 52. Neuroblastoma Chemotherapy Drugs Procurement Model
    Figure 53. Neuroblastoma Chemotherapy Drugs Sales Model
    Figure 54. Neuroblastoma Chemotherapy Drugs Sales Channels, Direct Sales, and Distribution
    Figure 55. Methodology
    Figure 56. Research Process and Data Source